Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1606-1610

  Lodise, T P ^a,b   Sorgel, F ^c   Melnick, D ^d,e   Mason, B ^d   Kinzig, M ^c   Drusano, G L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c IBMP   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INFUSION; DRUG PENETRATION; EPITHELIUM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BODY FLUIDS; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS INFECTIONS; TANDEM MASS SPECTROMETRY; THIENAMYCINS; YOUNG ADULT;

EID: 79953185012     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01330-10     Document Type: Article

References (29)

1. American Thoracic Society. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
2. Baldwin, D. R., R. Wise, J. M. Andrews, and D. Honeybourne. 1992. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies. J. Antimicrob. Chemother. 30:67-71.
3. Boselli, E., et al. 2003. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit. Care Med. 31:2102-2106.
4. Boselli, E., et al. 2008. Alveolar concentrations of piperacillin/ tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit. Care Med. 36:1500-1506.
5. Boselli, E., et al. 2004. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 30:989-991. (Pubitemid 38639498)
6. Boselli, E., D. Breilh, M. C. Saux, J. B. Gordien, and B. Allaouchiche. 2006. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med. 32:2059-2062. (Pubitemid 44833122)
7. Cars, O., and S. Ogren. 1985. Antibiotic tissue concentrations: methodological aspects and interpretation of results. Scand. J. Infect. Dis. Suppl. 44:7-15.
8. Cazzola, M., et al. 1995. Pulmonary penetration of ceftazidime. J. Chemother. 7:50-54.
9. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User's manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA. http://bmsr.usc.edu/.
10. Drusano, G. L., and M. Hutchison. 1995. The pharmacokinetics of meropenem. Scand. J. Infect. Dis. Suppl. 96:11-16.
11. Drusano, G. L., et al. 2004. Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis. 189:1590-1597.
12. Drusano, G. L., S. L. Preston, M. H. Gotfried, L. H. Danziger, and K. A. Rodvold. 2002. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 46:586-589.
13. Drusano, G. L., F. Sorgel, J. Quinn, B. Mason, and D. Melnick. 2005. Impact of pharmacodynamics dosing of meropenem on emergence of resistance during treatment of ventilator-associated pneumonia: a prospective clinical trial, abstr. K-127. 45th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC). American Society for Microbiology, Washington, DC.
14. Drusano, G. L., T. P. Lodise, F. Sorgel, B. Mason, and D. Melnick. 2008. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia, abstr. A-1899. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
15. Gotfried, M. H., L. H. Danziger, and K. A. Rodvold. 2003. Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects. J. Antimicrob. Chemother. 52:450-456.
16. Gotfried, M. H., L. H. Danziger, and K. A. Rodvold. 2001. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 119:1114-1122.
17. Gotfried, M. H., et al. 2008. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob. Agents Chemother. 52:92-97.
18. Iregui, M., S. Ward, G. Sherman, V. J. Fraser, and M. H. Kollef. 2002. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122:262-268.
19. Kollef, M. H., G. Sherman, S. Ward, and V. J. Fraser. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.
20. Leary, R., R. Jelliffe, A. Schumitzky, and M. van Guilder. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, pp. 389-394. Proc. 14th IEEE Symp. Comput. Based Med. Syst. IEEE Computer Society, Bethesda, MD.
21. Lodise, T. P. Jr., M. Gotfried, S. Barriere, and G. L. Drusano. 2008. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 52:2300-2304.
22. Lodise, T. P., et al. 2007. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J. Antimicrob. Chemother. 60:1038-1044.
23. Lodise, T. P., et al. 2005. Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn. Microbiol. Infect. Dis. 52:45-52.
24. Luna, C. M., et al. 2006. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur. Respir. J. 27:158-164.
25. Luna, C. M., et al. 1997. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111:676-685. (Pubitemid 27132946)
26. Muscedere, J. G., C. M. Martin, and D. K. Heyland. 2008. The impact of ventilator-associated pneumonia on the Canadian health care system. J. Crit. Care. 23:5-10.
27. Rodvold, K. A., L. H. Danziger, and M. H. Gotfried. 2003. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob. Agents Chemother. 47:2450-2457.
28. Rodvold, K. A., M. H. Gotfried, L. H. Danziger, and R. J. Servi. 1997. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41:1399-1402.
29. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.